Although the beneficial effects of SGLT2 inhibitors in treating cardiovascular and renal diseases, including HF and CKD, have been well-documented,[20] their benefits in AMI patients, particularly when administered before PCI, remain inadequately explored due to the absence of large-scale studies and meta-analyses. This evidence concerns the gene SLC5A2 and chronic kidney disease.